Programmes Industry Sessions



Industry Session by BLUE EARTH

Axumin™ (fluciclovine (18F)) – A Newly Approved Imaging Option for Recurrent Prostate Cancer – A Scientific Update

Thursday, 16 november
Room H1

12.05-12.10 Welcome and Introduction
Frode Willoch, Oslo (NO)

12.10-12.20 The FALCON Trial – A Phase 3 Study to assess the clinical utility of fluciclovine (18F) PET/CT imaging in patients with prostate cancer with biochemical recurrence

Fergus Gleeson, Oxford (GB)

12.20-12.35 Clinical Experience of fluciclovine (18F) PET/CT imaging in men with suspected recurrent prostate cancer and PSA values <1ng/mL
Frode Willoch, Oslo (NO)

12.35-12.50 Initial experience with using (18F) Fluciclovine in biochemically recurrent prostate cancer
Dirk Wyndaele, Eindhoven(NL)

12.50-13.00 Summary and closing remarks
Frode Willoch, Oslo (NO)



Industry Session by SANOFI GENZYME

Friday, 17 November

13.00-13.05 Welcome and introduction
Gero Kramer, Vienna (AT)

13.05-13.20 Individualizing treatment choices based on the biology of the disease
Yohann Loriot, Paris (FR)

13.20-13.35 Progresses and promises in the management of metastatic prostate cancer
Gero Kramer, Vienna (AT)

13.35-13.50 Translating the evidence into clinical practice
Amit Bahl, Bristol (GB)

13.50-14.00 Discussion and closing remarks
Chairman – faculty – audience



Industry Session by MSD

Immunotherapy Advances in Urologic Oncology

Friday, 17 November

17.45-17.50 Welcome and introductions
Cora Sternberg, Rome (IT)

17.50-18.05 Understanding the Mechanism of I-O Agents in GU Cancers
Thomas Powles, London (GB)

18.05-18.20 Latest Data Releases in I-O for mUC
Maria de Santis, Coventry (GB)

18.20-18.30 mUC Patient Case Studies
Jurgen Gschwend, Munich (DE)

18.30-18.40 Q & A session with panel

18.40-18.45 Closing Remarks
Cora Sternberg, Rome (IT)




Industry Session by IPSEN

Optimising treatment decisions in urological oncology

Saturday, 18 November

13.00-13.10 Welcome and introduction
Enrique Gallardo, Barcelona (ES)

13.10-13.30 Advanced prostate cancer: changing landscape for individualised treatment 
Peter Hammerer, Braunschweig (DE)

13.30-13.50 Advanced RCC: 2nd line treatment options
Cezary Szczylik, Warsaw (PL)

13.50-14.00 Summary & closing
Enrique Gallardo, Barcelona (ES)